Takeda Pharmaceutical Co. Ltd. intends to “rapidly” move its long-acting oral orexin drug for narcolepsy type 1 (NT1), TAK-861, into Phase III development after reporting positive topline results from a Phase IIb study of the drug, marking a change of fortunes from a little more than two years ago when its orexin franchise encountered a significant setback.
The drug maker released topline results 8 February from the randomized, double-blind, placebo-controlled and multiple-dose TAK-861-2001 study of the orexin receptor 2 (OX2R) agonist in 112 patients, saying it met primary and key secondary endpoints and showed the drug was generally safe and well-tolerated
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?